AIM ImmunoTech Announces \$2.65 Million At-Market Financing: What Investors Need to Know
Key Highlights
- Financing Amount and Structure: AIM ImmunoTech Inc. (NYSE American: AIM) has entered into definitive agreements for a registered direct offering and a concurrent private placement, with total gross proceeds expected to be approximately \$2.65 million, before deducting placement agent commissions and other offering expenses.
- Pricing: The financing is priced at-the-market under NYSE American rules, with shares sold at \$0.5189 per share.
- Placement Agent: Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering.
- Anticipated Closing: The offering is expected to close on or about June 10, 2026, subject to customary closing conditions.
Detailed Transaction Structure
- Registered Direct Offering: AIM will issue and sell 2,554,119 registered shares of common stock at \$0.5189 per share.
- Concurrent Private Placement: The company will also issue 2,554,119 unregistered shares of common stock (or pre-funded warrants in lieu thereof) at the same price and issue unregistered Class J warrants to purchase up to 10,216,476 shares of common stock. These Class J warrants have an exercise price of \$0.5189 per share, are exercisable subject to shareholder approval, and will expire five years from the initial exercise date.
- Regulatory Process: The registered shares will be offered via a prospectus supplement to the company’s shelf registration statement on Form S-3, declared effective by the SEC on July 3, 2025. The unregistered shares and warrants are to be issued in a private placement exempt from registration under Section 4(a)(2) of the Securities Act and Regulation D.
Use of Proceeds
The company intends to use the net proceeds for the following purposes:
- Manufacture of clinical drug supply
- Ongoing clinical trial activities
- Planned Phase 3 clinical trial activities
- Working capital purposes
Potential Impact on Shareholders and Valuation
- Dilution: The issuance of over 5 million new shares (registered and unregistered) and the potential for up to 10.2 million additional shares from the full exercise of the Class J warrants could significantly dilute existing shareholders.
- Shareholder Approval Requirement: The exercise of the Class J warrants is subject to shareholder approval, which could become a focal point for upcoming shareholder meetings.
- Use of Funds: The focus on manufacturing clinical supplies and funding clinical trials, including a planned Phase 3 trial, signals a commitment to advancing the company’s lead asset, Ampligen®, and could be viewed as a positive catalyst if these trials progress successfully.
- Regulatory and Clinical Risks: The company notes significant uncertainties related to clinical trial outcomes, regulatory approvals, and the sufficiency of funding. These risks should be carefully considered by investors as they may impact future share value.
About AIM ImmunoTech
AIM ImmunoTech is a clinical-stage immuno-pharma company focused on developing therapeutics for multiple cancers, immune disorders, and viral diseases, including COVID-19. Its lead product, Ampligen® (rintatolimod), is a first-in-class, highly selective TLR3 agonist immuno-modulator, currently in multiple clinical trials for globally significant cancers and immune-related diseases.
Forward-Looking Considerations
This financing enhances AIM ImmunoTech’s ability to execute its clinical and operational priorities, but the company remains subject to numerous risks, including the results and timing of clinical trials, regulatory approvals, and the ability to secure additional funding if needed. The issuance of new equity and warrants may impact share price both positively (if clinical milestones are met) and negatively (through dilution).
Investors are urged to closely monitor upcoming SEC filings, shareholder meeting materials, and trial updates for developments that could influence the company’s valuation.
Contact Information
For more information, visit aimimmuno.com or contact the company’s investor relations via [email protected].
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the company’s filings with the SEC and consult their own advisors before making any investment decisions. All forward-looking statements are subject to risks and uncertainties; actual results may differ materially from those anticipated.
